Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs

Abstract

Persistent reservoirs remain the major obstacles to achieve an HIV-1 cure. Prolonged early antiretroviral therapy (ART) may reduce the extent of reservoirs and allow for virological control after ART discontinuation. We compared HIV-1 reservoirs in a cross-sectional study using PCR-based techniques in blood and tissue of early treated seroconverters, late treated patients, ART-naïve seroconverters and long-term non-progressors (LTNPs) who have spontaneous virological control without treatment. A decade of early ART reduced total and integrated HIV-1 DNA levels compared to later treatment initiation, but not reaching the low levels of LTNPs. Total HIV-1 DNA in rectal biopsies did not differ between cohorts. Importantly, lower viral transcription (unspliced RNA) and enhanced immune preservation (CD4/CD8) reminiscent of LTNPs were found in early compared to late treated patients. This suggests that early treatment is associated with some immuno-virological features of LTNPs that may improve the outcome of future interventions aimed at a functional cure.

Article and author information

Author details

  1. Eva Malatinkova

    HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Universitair Ziekenhuis Gent, Ghent University, Ghent, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  2. Ward De Spiegelaere

    HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Universitair Ziekenhuis Gent, Ghent University, Ghent, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  3. Pawel Bonczkowski

    HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Universitair Ziekenhuis Gent, Ghent University, Ghent, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  4. Maja Kiselinova

    HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Universitair Ziekenhuis Gent, Ghent University, Ghent, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  5. Karen Vervisch

    HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Universitair Ziekenhuis Gent, Ghent University, Ghent, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  6. Wim Trypsteen

    HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Universitair Ziekenhuis Gent, Ghent University, Ghent, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  7. Margaret Johnson

    Division of Infection and Immunity, Royal Free Hospital, Royal Free London NHS Foundation Trust, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. Chris Verhofstede

    AIDS Reference Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  9. Danny de Looze

    Department of Gastroenterology, Universitair Ziekenhuis Gent, Ghent University, Ghent, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  10. Charles Murray

    Department of Gastroenterology, Royal Free Hospital, Royal Free London NHS Foundation Trust, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Sabine Kinloch-de Loes

    Division of Infection and Immunity, Royal Free Hospital, Royal Free London NHS Foundation Trust, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. Linos Vandekerckhove

    HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Universitair Ziekenhuis Gent, Ghent University, Ghent, Belgium
    For correspondence
    linos.vandekerckhove@ugent.be
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Quarraisha Abdool Karim, University of KwaZulu Natal, South Africa

Ethics

Human subjects: Patient written informed consent was obtained from all the study participants.The study was approved by the Ethical Committee of Ghent University Hospital (Reference number: B670201317826) and Royal Free Hospital (Reference number: 13/LO/0729).

Version history

  1. Received: June 5, 2015
  2. Accepted: October 1, 2015
  3. Accepted Manuscript published: October 6, 2015 (version 1)
  4. Version of Record published: November 17, 2015 (version 2)

Copyright

© 2015, Malatinkova et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,231
    views
  • 425
    downloads
  • 32
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Eva Malatinkova
  2. Ward De Spiegelaere
  3. Pawel Bonczkowski
  4. Maja Kiselinova
  5. Karen Vervisch
  6. Wim Trypsteen
  7. Margaret Johnson
  8. Chris Verhofstede
  9. Danny de Looze
  10. Charles Murray
  11. Sabine Kinloch-de Loes
  12. Linos Vandekerckhove
(2015)
Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs
eLife 4:e09115.
https://doi.org/10.7554/eLife.09115

Share this article

https://doi.org/10.7554/eLife.09115

Further reading

    1. Microbiology and Infectious Disease
    Magdalena Podkowik, Andrew I Perault ... Bo Shopsin
    Research Article

    The agr quorum-sensing system links Staphylococcus aureus metabolism to virulence, in part by increasing bacterial survival during exposure to lethal concentrations of H2O2, a crucial host defense against S. aureus. We now report that protection by agr surprisingly extends beyond post-exponential growth to the exit from stationary phase when the agr system is no longer turned on. Thus, agr can be considered a constitutive protective factor. Deletion of agr resulted in decreased ATP levels and growth, despite increased rates of respiration or fermentation at appropriate oxygen tensions, suggesting that Δagr cells undergo a shift towards a hyperactive metabolic state in response to diminished metabolic efficiency. As expected from increased respiratory gene expression, reactive oxygen species (ROS) accumulated more in the agr mutant than in wild-type cells, thereby explaining elevated susceptibility of Δagr strains to lethal H2O2 doses. Increased survival of wild-type agr cells during H2O2 exposure required sodA, which detoxifies superoxide. Additionally, pretreatment of S. aureus with respiration-reducing menadione protected Δagr cells from killing by H2O2. Thus, genetic deletion and pharmacologic experiments indicate that agr helps control endogenous ROS, thereby providing resilience against exogenous ROS. The long-lived ‘memory’ of agr-mediated protection, which is uncoupled from agr activation kinetics, increased hematogenous dissemination to certain tissues during sepsis in ROS-producing, wild-type mice but not ROS-deficient (Cybb−/−) mice. These results demonstrate the importance of protection that anticipates impending ROS-mediated immune attack. The ubiquity of quorum sensing suggests that it protects many bacterial species from oxidative damage.

    1. Medicine
    2. Microbiology and Infectious Disease
    Yi-Shin Chang, Kai Huang ... David L Perkins
    Research Article

    Background:

    End-stage renal disease (ESRD) patients experience immune compromise characterized by complex alterations of both innate and adaptive immunity, and results in higher susceptibility to infection and lower response to vaccination. This immune compromise, coupled with greater risk of exposure to infectious disease at hemodialysis (HD) centers, underscores the need for examination of the immune response to the COVID-19 mRNA-based vaccines.

    Methods:

    The immune response to the COVID-19 BNT162b2 mRNA vaccine was assessed in 20 HD patients and cohort-matched controls. RNA sequencing of peripheral blood mononuclear cells was performed longitudinally before and after each vaccination dose for a total of six time points per subject. Anti-spike antibody levels were quantified prior to the first vaccination dose (V1D0) and 7 d after the second dose (V2D7) using anti-spike IgG titers and antibody neutralization assays. Anti-spike IgG titers were additionally quantified 6 mo after initial vaccination. Clinical history and lab values in HD patients were obtained to identify predictors of vaccination response.

    Results:

    Transcriptomic analyses demonstrated differing time courses of immune responses, with prolonged myeloid cell activity in HD at 1 wk after the first vaccination dose. HD also demonstrated decreased metabolic activity and decreased antigen presentation compared to controls after the second vaccination dose. Anti-spike IgG titers and neutralizing function were substantially elevated in both controls and HD at V2D7, with a small but significant reduction in titers in HD groups (p<0.05). Anti-spike IgG remained elevated above baseline at 6 mo in both subject groups. Anti-spike IgG titers at V2D7 were highly predictive of 6-month titer levels. Transcriptomic biomarkers after the second vaccination dose and clinical biomarkers including ferritin levels were found to be predictive of antibody development.

    Conclusions:

    Overall, we demonstrate differing time courses of immune responses to the BTN162b2 mRNA COVID-19 vaccination in maintenance HD subjects comparable to healthy controls and identify transcriptomic and clinical predictors of anti-spike IgG titers in HD. Analyzing vaccination as an in vivo perturbation, our results warrant further characterization of the immune dysregulation of ESRD.

    Funding:

    F30HD102093, F30HL151182, T32HL144909, R01HL138628. This research has been funded by the University of Illinois at Chicago Center for Clinical and Translational Science (CCTS) award UL1TR002003.